The Purinergic P2X7 Receptor as a Target for Adjunctive Treatment for Drug-Refractory Epilepsy
International Journal of Molecular Sciences · 23.06.2024 · 25 (13) · 6894
DOI: 10.3390/ijms25136894 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 23.06.2024. Verfasst von Divyeshz Thakku Sivakumar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, University of Medicine and Health Sciences, D02 YN77 Dublin, Irel…. Hauptthemen laut MEDLINE: Receptors, Purinergic P2X7, Anticonvulsants, Purinergic P2X Receptor Antagonists, Drug Resistant Epilepsy. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 170 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science Foundation Ireland, National Natural Science Foundation of China, European Regional Development Fund.
Abstract (Originalsprache)
Epilepsy is one of the most common neurological diseases worldwide. Anti-seizure medications (ASMs) with anticonvulsants remain the mainstay of epilepsy treatment. Currently used ASMs are, however, ineffective to suppress seizures in about one third of all patients. Moreover, ASMs show no significant impact on the pathogenic mechanisms involved in epilepsy development or disease progression and may cause serious side-effects, highlighting the need for the identification of new drug targets for a more causal therapy. Compelling evidence has demonstrated a role for purinergic signalling, including the nucleotide adenosine 5′-triphosphate (ATP) during the generation of seizures and epilepsy. Consequently, drugs targeting specific ATP-gated purinergic receptors have been suggested as promising treatment options for epilepsy including the cationic P2X7 receptor (P27XR). P2X7R protein levels have been shown to be increased in the brain of experimental models of epilepsy and in the resected brain tissue of patients with epilepsy. Animal studies have provided evidence that P2X7R blocking can reduce the severity of acute seizures and the epileptic phenotype. The current review will provide a brief summary of recent key findings on P2X7R signalling during seizures and epilepsy focusing on the potential clinical use of treatments based on the P2X7R as an adjunctive therapeutic strategy for drug-refractory seizures and epilepsy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, University of Medicine and Health Sciences, D02 YN77 Dublin, Ireland.
- International College of Pharmaceutical Innovation, Soochow University, Suzhou 215123, China.
- Independent Researcher, 04275 Leipzig, Germany.
- FutureNeuro, Science Foundation Ireland Research Centre for Chronic and Rare Neurological Diseases, Royal College of Surgeons in Ireland, University of Medicine and Health Sciences, D02 YN77 Dublin, Ireland.
ORCID-Profile: Divyeshz Thakku Sivakumar, Yitao Wang, Tobias Engel
Förderung
- Science Foundation Ireland
- National Natural Science Foundation of China
- European Regional Development Fund
Zitieren
APA
Thakku Sivakumar, D., Jain, K., Alfehaid, N., Wang, Y., Teng, X., Fischer, W., & Engel, T. (2024). The Purinergic P2X7 Receptor as a Target for Adjunctive Treatment for Drug-Refractory Epilepsy. International Journal of Molecular Sciences, 25(13), 6894. https://doi.org/10.3390/ijms25136894
Vancouver
Thakku Sivakumar D, Jain K, Alfehaid N, Wang Y, Teng X, Fischer W, et al. The Purinergic P2X7 Receptor as a Target for Adjunctive Treatment for Drug-Refractory Epilepsy. International Journal of Molecular Sciences. 2024;25(13):6894. doi:10.3390/ijms25136894
BibTeX
@article{ThakkuSivakumar2024,
author = {Thakku Sivakumar, Divyeshz and Jain, Krishi and Alfehaid, Noura and Wang, Yitao and Teng, Xinchen and Fischer, Wolfgang and Engel, Tobias},
title = {The Purinergic P2X7 Receptor as a Target for Adjunctive Treatment for Drug-Refractory Epilepsy},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {13},
pages = {6894},
doi = {10.3390/ijms25136894}
}
EUVIMED